Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib

Gromicho,Marta; Magalhães,Marta; Torres,Fátima; Dinis,Joana; Fernandes,Alexandra   R.; Rendeiro,Paula; Tavares,Purificação; Laires,António; Rueff,José; Sebastião Rodrigues,António

doi:10.3892/or.2012.2153

Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib

Authors:
- Marta Gromicho
- Marta Magalhães
- Fátima Torres
- Joana Dinis
- Alexandra R. Fernandes
- Paula Rendeiro
- Purificação Tavares
- António Laires
- José Rueff
- António Sebastião Rodrigues
View Affiliations

Affiliations: Human Molecular Genetics Research Centre (CIGMH), Department of Genetics, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal, CGC (Clinical Genetics Center), Porto, Portugal, Department of Life Sciences, Faculty of Sciences and Technology, New University of Lisbon, Lisbon, Portugal
Published online on: November 28, 2012 https://doi.org/10.3892/or.2012.2153
Pages: 741-750

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the success of imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), approximately 30% of patients are resistant to therapy, mostly due to unknown causes. To profile the expression signatures of drug transporters throughout IM therapy and correlate them with resistance, we quantified mRNA expression levels of the SLC22A12, ABCB1, ABCC1, ABCG2 and MVP genes in consecutive samples from peripheral blood or bone marrow of CML patients who were either responsive or resistant to IM. Additionally we identified and quantified BCR-ABL1 transcript variants and analyzed 1236T>C ABCB1 and 480G>C SLC22A1 polymorphisms. A relationship between the type of BCR-ABL1 transcript or ABCB1 or SLC22A1 genotype and response to treatment was not discovered. However, the studied genes had higher expression levels in follow-up compared to the diagnostic samples, demonstrating a possible induction in expression. IM-sensitive patients presented significantly higher values of SLC22A1 expression, suggesting higher drug influx. Most importantly, while responding patients demonstrated stable expression signatures in consecutive samples, there was considerable variation in IM-resistant patients, indicating that single point sampling expression signatures are not reliable in predicting clinical outcomes or prognostic features in these patients. Studies that assessed consecutive samples from CML patients in order to evaluate the variation in expression levels of transporter genes are limited yet our study emphasizes the importance of such approaches.

View Figures

View References

1	Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood. 112:4808–4817. 2008. View Article : Google Scholar : PubMed/NCBI
2	Jabbour E, Cortes J and Kantarjian H: Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 117:897–906. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hochhaus A, O’Brien SG, Guilhot F, et al: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 23:1054–1061. 2009.PubMed/NCBI
4	de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 26:3358–3363. 2008.PubMed/NCBI
5	Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 112:4437–4444. 2008. View Article : Google Scholar
6	Baccarani M, Castagnetti F, Gugliotta G, Palandri F and Soverini S: Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 22:331–341. 2009. View Article : Google Scholar : PubMed/NCBI
7	Soverini S, Colarossi S, Gnani A, et al: Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 12:7374–7379. 2006. View Article : Google Scholar
8	Larson RA, Druker BJ, Guilhot F, et al: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111:4022–4028. 2008. View Article : Google Scholar : PubMed/NCBI
9	Picard S, Titier K, Etienne G, et al: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar : PubMed/NCBI
10	Thomas J, Wang L, Clark RE and Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 104:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI
11	White DL, Saunders VA, Dang P, et al: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110:4064–4072. 2007. View Article : Google Scholar : PubMed/NCBI
12	Clark RE, Davies A, Pirmohamed M and Giannoudis A: Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 49:639–642. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M and Clark R: Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 83:258–264. 2008. View Article : Google Scholar : PubMed/NCBI
14	Rodrigues AS, Dinis J, Gromicho M, Martins C, Laires A and Rueff J: Genomics and cancer drug resistance. Curr Pharm Biotechnol. 13:651–673. 2012. View Article : Google Scholar : PubMed/NCBI
15	Cortez MAA, Scrideli CA, Yunes JA, et al: mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatr Blood Cancer. 53:996–1004. 2009. View Article : Google Scholar
16	Raaijmakers MHGP: ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia. 21:2094–2102. 2007. View Article : Google Scholar
17	Steiner E, Holzmann K, Elbling L, Micksche M and Berger W: Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets. 7:923–934. 2006. View Article : Google Scholar : PubMed/NCBI
18	Vasconcelos FC, Silva KL, Souza PSD, et al: Variation of MDR protein expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 80:158–166. 2010.PubMed/NCBI
19	Stromskaya T, Rybalkina EY, Kruglov S, et al: Role of p-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry (Mosc). 73:29–37. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gromicho M, Dinis J, Magalhães M, et al: Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 52:1980–1990. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nijmeijer BA, Szuhai K, Goselink HM, et al: Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 37:376–385. 2009. View Article : Google Scholar : PubMed/NCBI
22	van Dongen JJ, Macintyre EA, Gabert JA, et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 13:1901–1928. 1999.PubMed/NCBI
23	Gabert J, Beillard E, van der Velden VHJ, et al: Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 17:2318–2357. 2003.
24	Schefe JH, Lehmann KE, Buschmann IR, Unger T and Funke-Kaiser H: Quantitative real-time RT-PCR data analysis: current concepts and the novel ‘gene expression’s CT difference’ formula. J Mol Med. 84:901–910. 2006.PubMed/NCBI
25	Crossman LC, Druker BJ, Deininger MWN, Pirmohamed M, Wang L and Clark RE: hOCT 1 and resistance to imatinib. Blood. 106:1133–1134. 2005. View Article : Google Scholar : PubMed/NCBI
26	Burger H, van Tol H, Brok M, et al: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Therapy. 4:747–752. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gardner ER, Sparreboom A, Verweij J and Figg WD: Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Therapy. 7:412–415. 2008. View Article : Google Scholar : PubMed/NCBI
28	Gurney H, Wong M, Balleine RL, et al: Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharm Ther. 82:33–40. 2007. View Article : Google Scholar : PubMed/NCBI
29	Xu C, Li CY-T and Kong A-NT: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 28:249–268. 2005. View Article : Google Scholar : PubMed/NCBI
30	Eechoute K, Sparreboom A, Burger H, et al: Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 17:406–415. 2011. View Article : Google Scholar : PubMed/NCBI
31	White DL, Saunders VA, Dang P, et al: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 108:697–704. 2006. View Article : Google Scholar
32	de Grouw EPLM, Raaijmakers MHGP, Boezeman JB, et al: Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34⁺CD38^- cells. Leukemia. 20:750–754. 2006.PubMed/NCBI
33	de Lavallade H, Finetti P, Carbuccia N, et al: A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Res. 34:254–257. 2010.PubMed/NCBI
34	Villuendas R, Steegmann JL, Pollán M, et al: Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 20:1047–1054. 2006. View Article : Google Scholar : PubMed/NCBI
35	Lange T, Günther C, Köhler T, et al: High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood. 101:2152–2155. 2003. View Article : Google Scholar : PubMed/NCBI
36	Czyzewski K and Styczynski J: Imatinib is a substrate for various multidrug resistance proteins. Neoplasma. 56:202–207. 2009. View Article : Google Scholar : PubMed/NCBI
37	Shukla S, Sauna ZE and Ambudkar SV: Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 22:445–447. 2008. View Article : Google Scholar : PubMed/NCBI
38	Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol. 12:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
39	White DL, Dang P, Engler J, et al: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 28:2761–2767. 2010. View Article : Google Scholar : PubMed/NCBI
40	Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP and White DL: Chronic myeloid leukemia CD34⁺ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 24:765–770. 2010.PubMed/NCBI
41	Hu S, Franke RM, Filipski KK, et al: Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 14:3141–3148. 2008. View Article : Google Scholar : PubMed/NCBI
42	O’Hare T, Eide CA and Deininger MWN: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 110:2242–2249. 2007.PubMed/NCBI
43	Redaelli S, Piazza R, Rostagno R, et al: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 27:469–471. 2008. View Article : Google Scholar : PubMed/NCBI
44	Wang L, Knight K, Lucas C and Clark RE: The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica. 91:235–239. 2006.PubMed/NCBI
45	Gruber FX, Lundán T, Goll R, et al: BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med Oncol. 29:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
46	Guilhot F, Apperley J, Kim D-W, et al: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 109:4143–4150. 2007. View Article : Google Scholar
47	Ernst T, Hoffmann J, Erben P, et al: ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 93:1389–1393. 2008. View Article : Google Scholar
48	Willis SG, Lange T, Demehri S, et al: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106:2128–2137. 2005. View Article : Google Scholar
49	Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H and Cortes J: Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph⁺ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 115:5428–5429. 2010. View Article : Google Scholar : PubMed/NCBI
50	Soverini S, Hochhaus A, Nicolini FE, et al: Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar
51	Sharma P, Kumar L, Mohanty S and Kochupillai V: Response to imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 89:241–247. 2010. View Article : Google Scholar : PubMed/NCBI
52	Polampalli S, Choughule A, Negi N, et al: Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genetics Mol Res. 7:1138–1149. 2008. View Article : Google Scholar : PubMed/NCBI
53	Lucas CM, Harris RJ, Giannoudis A, et al: Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 94:1362–1367. 2009. View Article : Google Scholar : PubMed/NCBI
54	Verma D, Kantarjian HM, Jones D, et al: Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 114:2232–2235. 2009. View Article : Google Scholar : PubMed/NCBI
55	Dulucq S, Bouchet S, Turcq B, et al: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 112:2024–2027. 2008. View Article : Google Scholar : PubMed/NCBI
56	Ni L-N, Li J-Y, Miao K-R, et al: Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 28:265–269. 2011. View Article : Google Scholar : PubMed/NCBI
57	Kim DHD, Sriharsha L, Xu W, et al: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 15:4750–4758. 2009. View Article : Google Scholar : PubMed/NCBI